Your browser doesn't support javascript.
loading
The genetics of hereditary cancer risk syndromes in Brazil: a comprehensive analysis of 1682 patients.
de Oliveira, Jarbas Maciel; Zurro, Nuria Bengala; Coelho, Antonio Victor Campos; Caraciolo, Marcel Pinheiro; de Alexandre, Rodrigo Bertollo; Cervato, Murilo Castro; Minillo, Renata Moldenhauer; de Vasconcelos Carvalho Neto, George; Grivicich, Ivana; Oliveira, João Bosco.
Afiliação
  • de Oliveira JM; Hospital Memorial Arcoverde, Arcoverde, Pernambuco, Brazil. jarbasmaciel@yahoo.com.br.
  • Zurro NB; Universidade Luterana do Brasil, Programa de Pós-Graduação em Biologia Celular e Molecular Aplicada à Saúde, Canoas, Rio Grande do Sul, Brazil. jarbasmaciel@yahoo.com.br.
  • Coelho AVC; Hospital Israelita Albert Einstein, São Paulo, Brazil.
  • Caraciolo MP; Hospital Israelita Albert Einstein, São Paulo, Brazil.
  • de Alexandre RB; Hospital Israelita Albert Einstein, São Paulo, Brazil.
  • Cervato MC; Hospital Israelita Albert Einstein, São Paulo, Brazil.
  • Minillo RM; Hospital Israelita Albert Einstein, São Paulo, Brazil.
  • de Vasconcelos Carvalho Neto G; Hospital Israelita Albert Einstein, São Paulo, Brazil.
  • Grivicich I; Hospital Israelita Albert Einstein, São Paulo, Brazil.
  • Oliveira JB; Universidade Luterana do Brasil, Programa de Pós-Graduação em Biologia Celular e Molecular Aplicada à Saúde, Canoas, Rio Grande do Sul, Brazil.
Eur J Hum Genet ; 30(7): 818-823, 2022 07.
Article em En | MEDLINE | ID: mdl-35534704
ABSTRACT
Hereditary cancer risk syndromes are caused by germline variants, commonly in tumor suppressor genes. Most studies on hereditary cancer have been conducted in white populations. We report the largest study in Brazilian individuals with multiple ethnicities. We genotyped 1682 individuals from all country regions with Next-generation sequencing (NGS) panels. Most were women with a personal/family history of cancer, mostly breast and ovarian. We identified 321 pathogenic/likely pathogenic (P/LP) variants in 305 people (18.1%) distributed among 32 genes. Most were on BRCA1 and BRCA2 (129 patients, 26.2% and 14.3% of all P/LP, respectively), MUTYH (42 monoallelic patients, 13.1%), PALB2 (25, 7.8%), Lynch syndrome genes (17, 5.3%), and TP53 (17, 5.3%). Transheterozygosity prevalence in our sample was 0.89% (15/1682). BRCA1/BRCA2 double heterozygosity rate was 0.78% (1/129) for BRCA variants carriers and 0.06% (1/1682) overall. We evaluated the performance of the genetic testing criteria by NCCN and the Brazilian National Health Agency (ANS). The inclusion criteria currently used in Brazil fail to identify 17%-25% of carriers of P/LP variants in hereditary cancer genes. Our results add knowledge on the Brazilian spectrum of cancer risk germline variants, demonstrate that large multigene panels have high positivity rates, and indicate that Brazilian inclusion criteria for genetic testing should be improved.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Síndromes Neoplásicas Hereditárias / Neoplasias da Mama Tipo de estudo: Etiology_studies / Prognostic_studies / Risk_factors_studies Limite: Female / Humans / Male País/Região como assunto: America do sul / Brasil Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Síndromes Neoplásicas Hereditárias / Neoplasias da Mama Tipo de estudo: Etiology_studies / Prognostic_studies / Risk_factors_studies Limite: Female / Humans / Male País/Região como assunto: America do sul / Brasil Idioma: En Ano de publicação: 2022 Tipo de documento: Article